Kyle Basham, MD
Urology · Fort Smith, ARNPI 1043573355
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Urogen Pharma, Inc. accounts for 61.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $15,664 and has fallen 87.2% since, to $2,006 in 2025.
Across 385 payments — averaging $79.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$19K
- Axonics, Inc.$2K
- Neotract Inc.$1K
- Procept Biorobotics Corporation$1K
- Medtronic$1K
- Boston Scientific$1K
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$16,15053%
- Travel & lodging$4,05613%
- Food & beverage$10,24934%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 35 | $18,594 |
| Axonics, Inc. | 30 | $2,344 |
| Neotract Inc. | 8 | $1,342 |
| Procept Biorobotics Corporation | 17 | $1,239 |
| Medtronic(2 entities) | 50 | $1,177 |
| Boston Scientific | 28 | $1,121 |
| Coloplast | 41 | $1,046 |
| Johnson & Johnson(2 entities) | 21 | $501 |
| Bayer | 21 | $476 |
| Sumitomo Pharma America, Inc. | 16 | $301 |
| Endo Pharmaceuticals Inc. | 10 | $267 |
| Astellas Pharma US Inc | 15 | $262 |
| Myriad Genetic Laboratories, Inc. | 11 | $231 |
| AbbVie(2 entities) | 13 | $219 |
| Myovant Sciences Inc. | 14 | $217 |
| Rochester Medical Corporation | 9 | $173 |
| Pfizer | 11 | $173 |
| Laborie Medical Technologies Corp. | 1 | $97 |
| Blue Earth Diagnostics | 4 | $90 |
| Teleflex LLC | 4 | $77 |
| Dendreon Pharmaceuticals LLC | 4 | $76 |
| Ambu Inc. | 2 | $75 |
| Olympus America Inc. | 2 | $62 |
| Progenics Pharmaceuticals, Inc. | 2 | $59 |
| Antares Pharma, Inc. | 3 | $44 |
| Cook Medical LLC | 3 | $39 |
| AstraZeneca | 2 | $34 |
| Urovant Sciences Inc | 2 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $18 |
| Photocure Inc | 1 | $18 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$17,992
- Bulkamid$1,681
- UroLift$1,220
- Axonics$954
- AquaBeam Robotic System$777
- Axonics r-SNM System$566
- Advantage System$391
- Solyx SIS System$245
- INTERSTIM$239
- TITAN$217
- XIAFLEX$125
- UPSYLON$117
- AQUABEAM SYSTEM$104
How this compares
$30,474 in reported general payments places this provider in the 85th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 13 | $194,368 |
| GemtesaVibegron | 143 | $78,947 |
| MyrbetriqMirabegron | 98 | $64,997 |
| OrgovyxRelugolix | 11 | $30,171 |
| Solifenacin Succinate | 188 | $4,658 |
| Estradiol | 65 | $3,498 |
| Tamsulosin Hcl | 469 | $3,160 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 78 | $1,640 |
| Trospium Chloride | 31 | $1,004 |
| Dutasteride | 51 | $985 |
| Finasteride | 96 | $909 |
| Testosterone Cypionate | 25 | $889 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 161 | $767 |
| Oxybutynin Chloride | 138 | $748 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $501 | $194,36813 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $301 | $109,119154 claims |
| Astellas Pharma US IncMyrbetriq | $262 | $64,99798 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 urology providers in Arkansas.
Other urology in Fort Smith
- John TerrellFort Smith$12K
- Ronald KnoblochFort Smith$5K
- John LangeFort Smith$2K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.